EP2804952A4 - Stabilization of the anti-cd20 antibody rituximab - Google Patents

Stabilization of the anti-cd20 antibody rituximab

Info

Publication number
EP2804952A4
EP2804952A4 EP12865606.3A EP12865606A EP2804952A4 EP 2804952 A4 EP2804952 A4 EP 2804952A4 EP 12865606 A EP12865606 A EP 12865606A EP 2804952 A4 EP2804952 A4 EP 2804952A4
Authority
EP
European Patent Office
Prior art keywords
stabilization
antibody rituximab
rituximab
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12865606.3A
Other languages
German (de)
French (fr)
Other versions
EP2804952A2 (en
Inventor
Rosemarie Wilton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therapeutic Proteins International LLC
Original Assignee
Therapeutic Proteins International LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeutic Proteins International LLC filed Critical Therapeutic Proteins International LLC
Publication of EP2804952A2 publication Critical patent/EP2804952A2/en
Publication of EP2804952A4 publication Critical patent/EP2804952A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
EP12865606.3A 2012-01-19 2012-01-19 Stabilization of the anti-cd20 antibody rituximab Withdrawn EP2804952A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/021888 WO2013109279A2 (en) 2012-01-19 2012-01-19 Stabilization of the anti-cd20 antibody rituximab

Publications (2)

Publication Number Publication Date
EP2804952A2 EP2804952A2 (en) 2014-11-26
EP2804952A4 true EP2804952A4 (en) 2015-09-09

Family

ID=48799789

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12865606.3A Withdrawn EP2804952A4 (en) 2012-01-19 2012-01-19 Stabilization of the anti-cd20 antibody rituximab

Country Status (7)

Country Link
EP (1) EP2804952A4 (en)
JP (1) JP2015506687A (en)
CN (1) CN104204217A (en)
AU (1) AU2012366290A1 (en)
CA (1) CA2861428A1 (en)
HK (1) HK1203561A1 (en)
WO (1) WO2013109279A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2871807C (en) * 2012-04-27 2022-10-04 Bioatla, Llc Modified antibody regions and uses thereof
ES2699599T3 (en) * 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Fc variants
US10611829B2 (en) 2014-01-31 2020-04-07 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
JP2019508415A (en) * 2016-02-10 2019-03-28 ケイマン ケミカル カンパニー， インコーポレーテッド Anti-citrullinated HLA polypeptide antibody and use thereof
CN107987160A (en) 2016-10-26 2018-05-04 无锡科捷诺生物科技有限责任公司 A kind of monoclonal antibody of no fucosylation
WO2021041300A2 (en) * 2019-08-23 2021-03-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
IL294257A (en) 2019-12-31 2022-08-01 Navrogen Inc Composition and use of engineered monoclonal antibodies refractory to tumor immuno-suppressive factors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020146750A1 (en) * 2000-03-30 2002-10-10 Hoogenboom Hendricus R.J.M. Mucin-1 specific binding members and methods of use thereof
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7232888B2 (en) * 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
JP4351674B2 (en) * 2002-12-16 2009-10-28 ジェネンテック・インコーポレーテッド Immunoglobulin variants and their use and use
CN1946741B (en) * 2004-03-31 2012-09-05 佳能株式会社 Gold-binding protein and its use
US20090060921A1 (en) * 2006-01-17 2009-03-05 Biolex Therapeutics, Inc. Glycan-optimized anti-cd20 antibodies
CA2729899A1 (en) * 2008-07-14 2010-01-21 Fred J. Stevens Methods for systematic control of protein stability
EA201100228A1 (en) * 2008-07-21 2011-08-30 Иммьюномедикс, Инк. STRUCTURAL VARIANTS OF ANTIBODIES TO IMPROVE THE THERAPEUTIC CHARACTERISTICS

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EWERT S ET AL: "Biophysical Properties of Human Antibody Variable Domains", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 325, no. 3, 17 January 2003 (2003-01-17), pages 531 - 553, XP027180832, ISSN: 0022-2836, [retrieved on 20030117], DOI: 10.1016/S0022-2836(02)01237-8 *
KASHMIRI S V S ET AL: "SDR grafting-a new approach to antibody humanization", METHODS, ACADEMIC PRESS, vol. 36, no. 1, 1 May 2005 (2005-05-01), pages 25 - 34, XP027216560, ISSN: 1046-2023, [retrieved on 20050419] *
MACCALLUM R M ET AL: "Antibody-antigen interactions: Contact analysis and binding site topography", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 262, no. 5, 1 January 1996 (1996-01-01), pages 732 - 745, XP002242391, ISSN: 0022-2836, DOI: 10.1006/JMBI.1996.0548 *

Also Published As

Publication number Publication date
CA2861428A1 (en) 2013-07-25
JP2015506687A (en) 2015-03-05
CN104204217A (en) 2014-12-10
AU2012366290A1 (en) 2014-08-07
WO2013109279A3 (en) 2014-04-17
EP2804952A2 (en) 2014-11-26
HK1203561A1 (en) 2015-10-30
WO2013109279A2 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
IL235985A0 (en) Immunoconjugates comprising anti-cd22 antibodies
IL235807A0 (en) Immunoconjugates comprising anti-cd79b antibodies
IL235989A0 (en) Immunoconjugates comprising anti-cd79b antibodies
IL233482B (en) Stabilized formulations containing anti-ang2 antibodies
IL235987A0 (en) Immunoconjugates comprising anti-cd22 antibodies
EP2841459A4 (en) Anti-cd22 antibodies
HK1203561A1 (en) Stabilization of the anti-cd20 antibody rituximab cd20
ZA201507844B (en) Bottle having axially opposed frustoconical portions
EP2994759A4 (en) Stabilization of labile analytes in reference materials
ZA201408213B (en) Anti-transglutaminase 2 antibodies
SG11201602869XA (en) Probiotic stabilization
HK1223307A1 (en) Novel compounds and uses thereof
HRP20180832T1 (en) Compounds for enhancing the cognitive function
EP2927243A4 (en) Anti-vasohibin 2 antibody
GB201322425D0 (en) Novel compounds and improved treatemtns for glaucoma
ZA201404909B (en) Stabilized formulations containing anti-ang2 antibodies
AU356535S (en) Fragrance bottle
AU356541S (en) Fragrance bottle
AU356542S (en) Fragrance bottle
GB201311051D0 (en) Fastening regions of material together
GB201209584D0 (en) Modified antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140715

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20150807

RIC1 Information provided on ipc code assigned before grant

Ipc: C12P 21/08 20060101AFI20150803BHEP

Ipc: C07K 16/00 20060101ALI20150803BHEP

Ipc: A61K 39/00 20060101ALI20150803BHEP

Ipc: C07K 16/28 20060101ALI20150803BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1203561

Country of ref document: HK

17Q First examination report despatched

Effective date: 20160413

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170124

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1203561

Country of ref document: HK